Global Blood Group Typing Market Grows Steadily at a CAGR of 9.80%

Introduction

Blood group typing is a diagnostic test determining an individual's blood type. A patient's blood group must be identified because not all blood types are compatible. Red blood cell surface antigens are used to determine blood categories. Antigens are substances that assist the body in distinguishing between its cells and potentially harmful foreign cells. The ABO system, utilized in blood type laboratory examinations, categorizes blood into four distinct groups: A, B, AB, and O. In addition, the Rh status of red blood cells, determined by a second mechanism known as the Rh system, is also established. A mismatch can result in a potentially fatal immunogenic reaction. Therefore, it is essential to comprehend both ABO and Rh varieties.

Market Dynamics

Increasing Number of Blood Donations drives the Global Market

In recent years, there has been a rise in the number of people donating blood. According to WHO data, voluntary unpaid blood donations in low- and middle-income countries have increased significantly. Between 2013 and 2018, 156 nations reported an increase of 7.8 million unpaid blood donations. The Western Pacific region (2.67 million donations) saw the largest rise in absolute numbers, followed by the Americas (2.66 million donations) and South-East Asia (2.37 million). The blood group typing test will also increase due to rising blood safety and availability standards.

Transforming Healthcare Infrastructure in Emerging Markets Creates Tremendous Opportunities 

In the coming years, hospitals in emerging markets will experience significant mid-tier and rural growth due to new hospital construction, expansion, and partnerships. Large hospitals networked with local clinics will increase to manage massive patient populations over the next few decades. This will provide neonatal care, integrative cancer treatment, and cardiac surgery and even serve as destinations for medical tourism where outcomes exceed Western standards at a fraction of the cost. In addition, the rise in patient education and early disease detection will drastically alter patients' expectations. Therefore, transforming healthcare in emerging and densely populated markets such as China and India will generate promising opportunities for market participants in the blood group typing industry.

 

Regional Analysis

North America is the most significant global blood group typing market shareholder and is expected to grow at a CAGR of 9.91% over the forecast period. The market for blood group typing in North America is expanding rapidly due to a rise in road accidents and the prevalence of chronic diseases. The Organization for Safe International Road Travel estimates that more than 38,000 people perish annually on American roads. In the United States, there are 12,4 fatalities per 100,000 persons on the roads. In addition, direct medical costs associated with traffic accidents cost the United States over USD 380 million. This will stimulate market demand for blood group typing during the forecast year. Likewise, the demand for blood transfusions in the United States is increasing. The American National Red Cross estimates that daily demand for RBCs exceeds 36,000 units and that approximately 21 million blood components are transfused annually in the United States. In each situation above, blood typing is an absolute necessity, and the market will grow as more of these situations arise.

Europe is estimated to exhibit a CAGR of 9.36% over the forecast period. Due to the swift market expansion in nations like the United Kingdom and France, Europe has substantial market expansion potential. The increasing prevalence of chronic diseases, rising healthcare expenditures, and robust R&D initiatives by market participants drive the growth of the European blood group typing market. In addition, Europe is regarded as the most vital market for blood group typing services and products due to numerous reimbursement initiatives for various surgical procedures and chronic diseases. According to the Global Cancer Observatory, the number of newly diagnosed cancer cases in Europe in 2018 exceeded 1.94 million. In addition to sedentary lifestyles and inappropriate diets, obesity and a shortage of physical activity are also attributed to the rising cancer incidence in Europe. Therefore, the increasing incidence and prevalence of cancer will boost the blood group typing market in Europe during the forecast period.

 

Key Highlights

• The global blood group typing market was valued at USD 3,716.40 million in 2022. It is estimated to reach USD 8,619.79 million by 2031, growing at a CAGR of 9.80% during the forecast period (2023–2031).
• Based on techniques, the global blood group typing market is bifurcated into PCR-based and microarray techniques, massively parallel sequencing, assay-based techniques, and others. The PCR-based and microarray technique segment dominates the global market and is estimated to exhibit a CAGR of 10.51% over the forecast period.
• Based on test type, the global blood group typing market is divided into human leukocyte antigen (HLA) typing, antibody screening, ABO blood tests, cross-matching series, and antigen typing. The antibody screening segment is the most significant contributor to the market and is estimated to exhibit a CAGR of 10.50% over the forecast period.
• Based on product type, the global blood group typing market is divided into instruments, services, and consumables. The consumables segment owns the largest market share and is estimated to exhibit a CAGR of 10.14% over the forecast period.
• Based on end-user, the global blood group typing market is bifurcated into clinical laboratories, blood banks, hospitals, and others. The blood banks segment dominates the global market and is predicted to grow at a CAGR of 10.29% during the forecast period.
• North America is the most significant global blood group typing market shareholder and is expected to grow at a CAGR of 9.91% over the forecast period.

Competitive Players

1. Quotient Limited
2. Immucor Inc.
3. Merck KGaA
4. DIAGAST
5. The Novacyt Group
6. Agena Bioscience Inc.
7. BAG Diagnostics Gmbh
8. AXO Science
9. Grifols S.A.
10. Rapid Labs Limited

Recent Developments

• June 2022- Grifols, a world leader in the development of plasma-derived therapies and innovative diagnostic solutions, announced today that its Procleix Plasmodium Assay had received the CE mark, the first for an automated nucleic acid test (NAT) system validated for screening blood donors for malaria.

• July 2022- Quotient Limited entered into a contract with InfYnity Biomarkers to add blood screening tests to MosaiQ's infectious disease menu.

Segmentation

1. By Techniques
   1. PCR-Based and Microarray Technique
   2. Massively Parallel Sequencing
   3. Assay-based Techniques
   4. Others
2. By Test Type
   1. Human Leukocyte Antigen (HLA) Typing
   2. Antibody Screening
   3. ABO Blood Tests
   4. Cross-matching Series
   5. Antigen Typing
3. By Products Type
   1. Instruments
   2. Services
   3. Consumables
4. By End-User
   1. Clinical Laboratories
   2. Blood Banks
   3. Hospitals
   4. Others